AbbVie Inc.

Guidance Including the Impact of Acquired IPR&D and Milestones Expense

(Unaudited)

(in millions, except per share data)	Quarter Ended June 30, 2024						Full-Year Ended December 31, 2024
	Acquired IPR&D and Milestones Expense		Adjusted Diluted EPS Range				Acquired IPR&D and Milestones Expense		Adjusted Diluted EPS Range
			Low		High				Low		High
Previously announced guidance excluding Q2 2024 acquired IPR&D and milestones expense	$	—	$	3.05	$	3.09	$	164	$	11.13	$	11.33
Q2 2024 acquired IPR&D and milestones expense	937		(0.52)		(0.52)		937		(0.52)		(0.52)
Guidance including Q2 2024 acquired IPR&D and milestones expensea	$	937	$	2.53	$	2.57	$	1,101	$	10.61	$	10.81

a    The Company's 2024 adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones expense that may be incurred beyond the second quarter of 2024, as both cannot be reliably forecasted.

    1